» Articles » PMID: 19011195

The Effect of Diffuse Pulmonary Fibrosis on the Reliability of CT Signs of Pulmonary Hypertension

Overview
Journal Radiology
Specialty Radiology
Date 2008 Nov 18
PMID 19011195
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine whether pulmonary artery (PA) dilatation is a reliable indicator of pulmonary hypertension (PH) in patients with pulmonary fibrosis.

Materials And Methods: This study had institutional review board approval. Patient consent was not required. Seventy-seven patients (39 men, 38 women) who underwent right heart catheterization were studied. The study population was divided into 30 patients with pulmonary fibrosis (group A), and 47 without (group B). The main PA diameter (dPA) and ascending aorta diameter (dAA) were measured by using computed tomography (CT), and the extent of fibrosis was recorded in group A. The dPA and the dPA/dAA ratio were correlated (Spearman rank) with mean PA pressure (mPAP) and pulmonary vascular resistance index (PVRi). The relationship between dPA and pulmonary fibrosis extent and total lung capacity (TLC) was examined by using multivariate linear regression.

Results: There were strong correlations between dPA and both mPAP (r = 0.67, P < .0001) and PVRi (r = 0.78, P < .0001) in group B. In contrast, there were no significant correlations in group A (r = 0.23, P = .22 for mPAP and r = 0.23, P = .28 for PVRi). The dPA/dAA ratio had similar relationships to dPA alone in group B (r = 0.72, P < .0001 for mPAP and r = 0.71, P < .0001 for PVRi), but significantly strengthened the correlations in group A (r = 0.54, P < .005 for mPAP and r = 0.48, P = .04 for PVRi). PA dilatation occurred in group A in the absence of significant PH, and was unrelated to CT fibrosis score or TLC.

Conclusion: PA dilatation occurs in the absence of PH in patients with pulmonary fibrosis and is therefore an unreliable sign of PH in these patients.

Citing Articles

Determining pulmonary artery diameter on CT scans as basis for performing transthoracic echocardiography to screen for pulmonary hypertension in patients with pulmonary artery enlargement.

Ouchi K, Sakuma T, Akao R, Nojiri A, Kawai M, Ojiri H J Echocardiogr. 2024; .

PMID: 39720970 DOI: 10.1007/s12574-024-00674-8.


Noninvasive diagnostic modalities and prediction models for detecting pulmonary hypertension associated with interstitial lung disease: a narrative review.

Arvanitaki A, Diller G, Gatzoulis M, McCabe C, Price L, Wort S Eur Respir Rev. 2024; 33(174).

PMID: 39384306 PMC: 11462299. DOI: 10.1183/16000617.0092-2024.


CCL18, CHI3L1, ANG2, IL-6 systemic levels are associated with the extent of lung damage and radiomic features in SARS-CoV-2 infection.

Ferrigno I, Verzellesi L, Ottone M, Bonacini M, Rossi A, Besutti G Inflamm Res. 2024; 73(4):515-530.

PMID: 38308760 DOI: 10.1007/s00011-024-01852-1.


Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary....

Piccari L, Allwood B, Antoniou K, Chung J, Hassoun P, Nikkho S Pulm Circ. 2023; 13(2):e12213.

PMID: 37025209 PMC: 10071306. DOI: 10.1002/pul2.12213.


Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection.

Parikh R, Konstantinidis I, OSullivan D, Farber H Pulm Circ. 2022; 12(4):e12141.

PMID: 36225536 PMC: 9531548. DOI: 10.1002/pul2.12141.